Linganisha mbinu

	Kiwango cha Ubora wa Maisha wa Rhinoconjunctivitis	Kiwango cha Tathmini ya Ugumu wa Kupumua cha Baraza la Utafiti wa Matibabu
Nyanja	Pulmonolojia	Pulmonolojia
Familia	Process / pipeline	Process / pipeline
Mwaka wa asili	1996	1959
Mwanzilishi	Elizabeth F. Juniper, McMaster University	Medical Research Council (UK)
Aina	Self-report questionnaire	Clinician or self-rated ordinal scale
Chanzo asilia	Juniper, E. F., Guyatt, G. H., Streiner, D. L., & King, D. R. (1996). Clinical validation and responsiveness of three scales developed to measure the effect of allergic rhinitis on quality of life. Journal of Clinical Epidemiology, 49(3), 339-347.	Van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988). Interobserver agreement for the assessment of handicap in stroke patients. Stroke, 19(5), 604-607.
Majina mbadala	RQLQ, Rhinoconjunctivitis QoL	MRC, MRC Dyspnea, Modified Borg
Zinazohusiana	5	5
Muhtasari	The RQLQ is a 28-item disease-specific quality-of-life instrument developed by Juniper and colleagues at McMaster University in 1996 to assess the impact of allergic rhinitis and allergic conjunctivitis on daily functioning. It captures symptom burden and activity limitation across seven domains: sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, activity limitation, and emotional function. The RQLQ is the preferred outcome measure in allergic rhinitis clinical trials and is widely used in allergy and immunology practice to track treatment response.	The MRC Dyspnoea Scale is a simple 5-grade ordinal classification of dyspnea severity based on the exertional threshold at which breathlessness limits activity. Developed by the UK Medical Research Council (MRC) in 1959, it remains one of the most widely used dyspnea assessments globally due to its brevity, ease of administration, and strong prognostic correlation in chronic obstructive pulmonary disease and other chronic respiratory diseases. The scale is used in clinical practice, epidemiological surveys, and longitudinal disease monitoring to grade symptom severity and guide treatment intensity.